The US Food and Drug Administration (FDA) has approved GSK’s triazaacenaphthylene antibiotic, Blujepa (gepotidacin), for ...

GSK's pill, the first oral antibiotic for urinary tract infections in almost 30 years, comes as bacteria are increasingly becoming treatment-resistant.

The drug is a needed new option for treating uncomplicated UTIs, a common infection that’s becoming harder to treat as rates ...

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...

GSK received approval from the Food and Drug Administration for Blujepa to be used as a treatment for some urinary tract infections. Blujepa, or gepotidacin, was approved to treat uncomplicated ...

A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

GSK (LSE:GSK) recently announced the FDA approval of Blujepa, a first-in-class antibiotic for urinary tract infections, and ...

The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.

If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...

GSK (GSK) plc announced that the U.S. Food and Drug Administration has approved Blujepa for the treatment of female adults and pediatric patients with uncomplicated urinary tract infections caused ...

GSK plc GSK announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract infections (uUTIs) in female adults and adolescents. A commercial launch for ...